tiprankstipranks
Advertisement
Advertisement

TAK Stock Latest News

Takeda Targets China PV Market With New Rusfertide Trial
Company AnnouncementsTakeda Targets China PV Market With New Rusfertide Trial
2d ago
TAK
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
PremiumRatings
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
3d ago
TAK
Takeda award from Veterans Affairs posted to SAM.gov site
PremiumThe Fly
Takeda award from Veterans Affairs posted to SAM.gov site
6d ago
TAK
Takeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch
PremiumCompany Announcements
Takeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch
9d ago
TAK
Takeda Targets High-Need Psoriasis Niche With New Phase 3b Zasocitinib Study
PremiumCompany Announcements
Takeda Targets High-Need Psoriasis Niche With New Phase 3b Zasocitinib Study
9d ago
TAK
Takeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance
PremiumCompany AnnouncementsTakeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance
9d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
Premium
The Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
11d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
Premium
The Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
11d ago
TAK
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
PremiumCompany Announcements
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
12d ago
TAK
Takeda Advances Pediatric Pouchitis Trial, Extending Entyvio’s Long‑Term Growth Story
PremiumCompany Announcements
Takeda Advances Pediatric Pouchitis Trial, Extending Entyvio’s Long‑Term Growth Story
13d ago
TAK
Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder
PremiumCompany Announcements
Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder
16d ago
TAK
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
PremiumThe Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
17d ago
TAK
KROS
Takeda’s Rusfertide Trial in Japan Adds Momentum to Its Rare Blood Cancer Pipeline
PremiumCompany AnnouncementsTakeda’s Rusfertide Trial in Japan Adds Momentum to Its Rare Blood Cancer Pipeline
17d ago
TAK
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
Premium
Ratings
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
17d ago
TAK
Takeda’s Pediatric GERD Trial Update: What Dexlansoprazole Data Could Mean for TAK Investors
Premium
Company Announcements
Takeda’s Pediatric GERD Trial Update: What Dexlansoprazole Data Could Mean for TAK Investors
18d ago
TAK
Takeda Targets Infection Risks in Older IBD Patients With New ENTYVIO Safety Study
PremiumCompany Announcements
Takeda Targets Infection Risks in Older IBD Patients With New ENTYVIO Safety Study
20d ago
TAK
Takeda Deepens Its Rare Disease Data Moat With New AATD Liver Study
PremiumCompany Announcements
Takeda Deepens Its Rare Disease Data Moat With New AATD Liver Study
23d ago
TAK
Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK
PremiumCompany Announcements
Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK
23d ago
TAK
Takeda dengue vaccine receives marketing authorization from India DCGI
PremiumThe Fly
Takeda dengue vaccine receives marketing authorization from India DCGI
26d ago
TAK
Takeda’s TAK-226 Anemia Trial Offers New Optionality in Hematology
PremiumCompany AnnouncementsTakeda’s TAK-226 Anemia Trial Offers New Optionality in Hematology
1M ago
TAK
Takeda Extends TAK-360 Sleep Trial, Signaling Long-Term Ambitions in Narcolepsy
Premium
Company Announcements
Takeda Extends TAK-360 Sleep Trial, Signaling Long-Term Ambitions in Narcolepsy
1M ago
TAK
Takeda’s Takhzyro Real‑World Pediatric Study Wraps Up, Setting the Stage for Next Moves
Premium
Company Announcements
Takeda’s Takhzyro Real‑World Pediatric Study Wraps Up, Setting the Stage for Next Moves
1M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >